ATE412665T1 - Reinigung von hbv-antigenen zur verwendung in impfstoffen - Google Patents

Reinigung von hbv-antigenen zur verwendung in impfstoffen

Info

Publication number
ATE412665T1
ATE412665T1 AT05077471T AT05077471T ATE412665T1 AT E412665 T1 ATE412665 T1 AT E412665T1 AT 05077471 T AT05077471 T AT 05077471T AT 05077471 T AT05077471 T AT 05077471T AT E412665 T1 ATE412665 T1 AT E412665T1
Authority
AT
Austria
Prior art keywords
vaccines
purification
hbv antigens
hbv
antigens
Prior art date
Application number
AT05077471T
Other languages
English (en)
Inventor
Heyer Koen De
Peter Schu
Michelle Serantoni
Opstel Omer Van
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0019728.5A external-priority patent/GB0019728D0/en
Priority claimed from GB0101334A external-priority patent/GB0101334D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE412665T1 publication Critical patent/ATE412665T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05077471T 2000-08-10 2001-08-07 Reinigung von hbv-antigenen zur verwendung in impfstoffen ATE412665T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment
GB0101334A GB0101334D0 (en) 2001-01-18 2001-01-18 Novel compounds

Publications (1)

Publication Number Publication Date
ATE412665T1 true ATE412665T1 (de) 2008-11-15

Family

ID=26244821

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05077471T ATE412665T1 (de) 2000-08-10 2001-08-07 Reinigung von hbv-antigenen zur verwendung in impfstoffen
AT01960630T ATE313558T1 (de) 2000-08-10 2001-08-07 Reinigung von hbv-antigenen zur verwendung in impfstoffen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01960630T ATE313558T1 (de) 2000-08-10 2001-08-07 Reinigung von hbv-antigenen zur verwendung in impfstoffen

Country Status (35)

Country Link
US (3) US20030235590A1 (de)
EP (2) EP1666487B1 (de)
JP (2) JP2004505992A (de)
KR (1) KR100804922B1 (de)
CN (1) CN1468256B (de)
AP (1) AP2003002734A0 (de)
AR (1) AR030325A1 (de)
AT (2) ATE412665T1 (de)
AU (2) AU8207301A (de)
BG (1) BG66038B1 (de)
BR (1) BRPI0113155C1 (de)
CA (2) CA2740282A1 (de)
CY (2) CY1106310T1 (de)
CZ (1) CZ303217B6 (de)
DE (2) DE60136400D1 (de)
DK (2) DK1666487T3 (de)
DZ (1) DZ3470A1 (de)
EA (1) EA006433B1 (de)
EG (1) EG25829A (de)
ES (2) ES2254464T3 (de)
HU (1) HU228932B1 (de)
IL (2) IL154301A0 (de)
MX (1) MXPA03001235A (de)
MY (1) MY128999A (de)
NO (1) NO20030635L (de)
NZ (1) NZ524012A (de)
OA (1) OA12361A (de)
PE (1) PE20020287A1 (de)
PL (1) PL204736B1 (de)
PT (1) PT1666487E (de)
SI (2) SI1307473T1 (de)
SK (2) SK288079B6 (de)
UA (1) UA79735C2 (de)
UY (1) UY26882A1 (de)
WO (1) WO2002012287A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0202901D0 (en) * 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
CN101262883A (zh) * 2005-07-11 2008-09-10 环球免疫公司 引发针对靶向的疗法的逃逸突变体的免疫应答的组合物和方法
PL1909830T3 (pl) * 2005-08-02 2012-02-29 Novartis Vaccines And Diagnostics S R L Ograniczenie oddziaływania pomiędzy olejem w adiuwancie a środkiem powierzchniowo czynnym w antygenie
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0612142D0 (en) 2006-06-20 2006-08-02 Secr Defence Spreading modulation spectrum control
PT2097102E (pt) 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US8436514B2 (en) * 2007-10-30 2013-05-07 Kyocera Corporation Acoustic wave device comprising an inter-digital transducer electrode
US8250102B2 (en) * 2008-03-14 2012-08-21 Microsoft Corporation Remote storage and management of binary object data
KR100959145B1 (ko) 2008-03-21 2010-05-25 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
SG176220A1 (en) * 2009-05-27 2011-12-29 Glaxosmithkline Biolog Sa Casb7439 constructs
WO2012095834A1 (en) * 2011-01-14 2012-07-19 Hal Allergy Holding B.V. Immunoassay for direct determination of antigen content of products comprising adjuvant-coupled-antigen particles
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN111032078A (zh) 2017-07-18 2020-04-17 血清研究所印度私人有限公司 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
JP2022524007A (ja) 2019-03-05 2022-04-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｂ型肝炎免疫化レジメンおよび組成物
EP4074336A4 (de) * 2019-12-13 2024-09-04 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmazeutische zusammensetzung und verwendung davon

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1030777A (en) * 1963-12-06 1966-05-25 Ciba Ltd Method of preparing a vaccine against trypanosoma cruzi infections
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
EP0135435A3 (de) 1983-08-22 1987-03-25 Merck & Co. Inc. Immunogenisches HBsAg aus transformierter Hefe stammend
US4683294A (en) 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0304578B1 (de) 1987-06-22 2001-10-24 Medeva Holdings Bv Hepatitis-B-Oberflächenantigen enthaltendes Peptid
EP0299108B1 (de) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung
EP0314240A3 (de) * 1987-10-26 1990-03-28 Merck & Co. Inc. Verfahren für de Reinigung von rekombinanten Hepatitis-Antigenen
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5274081A (en) * 1989-09-20 1993-12-28 Immuno A.G. Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
AU9052091A (en) 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
JP3026029B2 (ja) 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
EP0533492A3 (en) 1991-09-18 1994-08-10 Amgen Inc A hepatitis b vaccine formulation incorporating a bile acid salt
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0671948B1 (de) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Adjuvantien enthaltende impfstoffzusammensetzung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
BR9509903A (pt) * 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2324289C (en) * 1998-03-09 2010-07-13 Smithkline Beecham Biologicals S.A. Combined vaccine compositions
AU773204C (en) 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
JP2002532116A (ja) * 1998-12-23 2002-10-02 メルク エンド カムパニー インコーポレーテッド 改良された組換えｂ型肝炎表面抗原
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах

Also Published As

Publication number Publication date
UY26882A1 (es) 2002-03-22
HUP0302951A3 (en) 2004-10-28
CY1108789T1 (el) 2014-04-09
SK288069B6 (sk) 2013-05-03
CA2427475C (en) 2011-07-05
BG107545A (bg) 2004-01-30
EP1307473A1 (de) 2003-05-07
KR100804922B1 (ko) 2008-02-20
NO20030635L (no) 2003-04-01
WO2002012287A1 (en) 2002-02-14
CZ2003385A3 (cs) 2003-06-18
US20030235590A1 (en) 2003-12-25
CZ303217B6 (cs) 2012-05-30
ES2314555T3 (es) 2009-03-16
MY128999A (en) 2007-03-30
JP5559847B2 (ja) 2014-07-23
DK1666487T3 (da) 2009-01-12
JP2004505992A (ja) 2004-02-26
BRPI0113155C1 (pt) 2021-05-25
SI1307473T1 (sl) 2006-04-30
US8624004B2 (en) 2014-01-07
IL154301A (en) 2009-11-18
HK1056884A1 (en) 2004-03-05
DE60116107D1 (de) 2006-01-26
CA2740282A1 (en) 2002-02-11
KR20030029127A (ko) 2003-04-11
ATE313558T1 (de) 2006-01-15
MXPA03001235A (es) 2004-07-16
DK1307473T3 (da) 2006-05-01
DZ3470A1 (fr) 2002-02-14
EP1666487A1 (de) 2006-06-07
DE60136400D1 (de) 2008-12-11
CN1468256A (zh) 2004-01-14
AU8207301A (en) 2002-02-18
PE20020287A1 (es) 2002-06-20
HUP0302951A2 (hu) 2003-12-29
PL362322A1 (en) 2004-10-18
EA006433B1 (ru) 2005-12-29
CA2427475A1 (en) 2002-02-11
IL154301A0 (en) 2003-09-17
PT1666487E (pt) 2008-12-26
BR0113155A (pt) 2003-07-08
UA79735C2 (uk) 2007-07-25
HU228932B1 (en) 2013-06-28
BG66038B1 (bg) 2010-11-30
DE60116107T2 (de) 2006-08-03
EG25829A (en) 2012-09-02
AP2003002734A0 (en) 2003-03-31
EP1307473B1 (de) 2005-12-21
AR030325A1 (es) 2003-08-20
BRPI0113155B8 (pt) 2019-08-13
AU2001282073B2 (en) 2005-01-20
PL204736B1 (pl) 2010-02-26
CY1106310T1 (el) 2011-10-12
ES2254464T3 (es) 2006-06-16
SK288079B6 (sk) 2013-06-03
US20060159705A1 (en) 2006-07-20
US20090123496A1 (en) 2009-05-14
NZ524012A (en) 2004-02-27
BRPI0113155B1 (pt) 2018-11-21
NO20030635D0 (no) 2003-02-07
OA12361A (en) 2004-04-13
JP2012255015A (ja) 2012-12-27
EA200300129A1 (ru) 2003-10-30
SK1692003A3 (en) 2003-08-05
SI1666487T1 (sl) 2009-02-28
CN1468256B (zh) 2010-10-27
EP1666487B1 (de) 2008-10-29

Similar Documents

Publication Publication Date Title
ATE412665T1 (de) Reinigung von hbv-antigenen zur verwendung in impfstoffen
DE69928763D1 (de) Adjuvanzien zur Verwendung in Impfstoffen
DE60134866D1 (de) Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung
DE60109579D1 (de) Stabilisierte kieselsäure und verfahren zur herstellung und verwendung derselben
DE60103137D1 (de) Impstoff zur behandlung von atherosclerosis
DE60111747D1 (de) Verfahren zur herstellung von infektiösen reoviren
CY2013025I2 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
DE60114348D1 (de) Verfahren zur Reinigung von Gasen
DE60106104D1 (de) Verfahren zur Absorption von Acrylsäure und Verfahren zur Reinigung von Acrylsäure
DE50006193D1 (de) Verfahren zur herstellung von otoplastiken und otoplastik
ATE277920T1 (de) Verfahren zur vorbereitung von reinem citalopram
DE60117106D1 (de) Verfahren zur Herstellung von Halopropyldimethylchlorosilanen
DE50103049D1 (de) Verfahren zur Herstellung von Aminodiphenylaminen
DE60026607T8 (de) Verfahren zur Herstellung von Perfluoralkadienen
DE50107279D1 (de) Autoklav zur präzisionsreinigung von stücken und verwendung des autoklavs
DE60031108D1 (de) Verfahren zur Herstellung von Vinylamin-Vinylalkohol-Copolymeren und Verwendung davon
DE60128640D1 (de) Verfahren zur Herstellung von optisch aktivem 4-Halo-3-Hydroxybutanoat
DE60123013D1 (de) Verfahren zur herstellung von glasskeramiken
ATE439855T1 (de) Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung
DE60236649D1 (de) Methode zur entfernung von allergenen
DE60118367D1 (de) Verfahren zur fluormethylierung von alkoholen
DE60112390D1 (de) Verfahren zur Herstellung von Isobuten-Isopren Kopolymeren
DE50013395D1 (de) Verfahren zur Herstellung von ÄIrCODClÜ2
DE60120139D1 (de) Verfahren zur herstellung von camptothectin
DE60119491D1 (de) Verfahren zur herstellung von acetylamidiniophenylalanyl-cyclohexylglycyl-pyridylalaninamiden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1666487

Country of ref document: EP